Terms: = Breast cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
22 results:
1. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract] [Full Text] [Related]
2. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
[TBL] [Abstract] [Full Text] [Related]
3. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
[TBL] [Abstract] [Full Text] [Related]
4. Improving surgical efficiency of immediate implant-based breast reconstruction following mastectomy.
Nealon K; Rebello M; Sobti N; Sherburne A; Spracklin D; Liao EC; Specht M
Breast Cancer Res Treat; 2019 Jul; 176(1):159-164. PubMed ID: 30977025
[TBL] [Abstract] [Full Text] [Related]
5. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract] [Full Text] [Related]
6. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract] [Full Text] [Related]
7. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation.
Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
[TBL] [Abstract] [Full Text] [Related]
8. Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy.
Li X; Wang S; Ren H; Ma J; Sun X; Li N; Liu C; Huang K; Xu M; Ming L
Cancer Biol Ther; 2016 Jun; 17(6):684-92. PubMed ID: 27224726
[TBL] [Abstract] [Full Text] [Related]
9. cd117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival.
Tan WJ; Thike AA; Tan SY; Tse GM; Tan MH; Bay BH; Tan PH
Mod Pathol; 2015 Mar; 28(3):352-8. PubMed ID: 25216225
[TBL] [Abstract] [Full Text] [Related]
10. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract] [Full Text] [Related]
11. Soluble kit correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Keyvanjah K; DePrimo SE; Harmon CS; Huang X; Kern KA; Carley W
J Transl Med; 2012 Aug; 10():165. PubMed ID: 22897944
[TBL] [Abstract] [Full Text] [Related]
12. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
Monhollen L; Morrison C; Ademuyiwa FO; Chandrasekhar R; Khoury T
Histopathology; 2012 Sep; 61(3):365-77. PubMed ID: 22486370
[TBL] [Abstract] [Full Text] [Related]
13. Basal-like breast carcinoma: a phenotypically distinct entity.
Haupt B; Ro JY; Schwartz MR
Arch Pathol Lab Med; 2010 Jan; 134(1):130-3. PubMed ID: 20073617
[TBL] [Abstract] [Full Text] [Related]
14. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.
Charpin C; Secq V; Giusiano S; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Int J Cancer; 2009 May; 124(9):2124-34. PubMed ID: 19142869
[TBL] [Abstract] [Full Text] [Related]
15. An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer.
Egervari K; Toth J; Nemes Z; Szollosi Z
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):247-54. PubMed ID: 19098680
[TBL] [Abstract] [Full Text] [Related]
16. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
[TBL] [Abstract] [Full Text] [Related]
17. breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract] [Full Text] [Related]
19. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract] [Full Text] [Related]
[Next]
